Lundbeck loses bid for damages increase in Lexapro patent case
Clayton Utz 2019-01-30 1:19 pm By Cat Fredenburgh
Please login to bookmark Close

Denmark-based Lundbeck cannot recover damages for the alleged infringement of its Lexapro patent by generic drug companies that it dropped its claims against, a judge has found.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au